<DOC>
	<DOCNO>NCT01137708</DOCNO>
	<brief_summary>This study design ass whether co-administration CP-690,550 oral contraceptive effect metabolism oral contraceptive healthy volunteer .</brief_summary>
	<brief_title>CP-690,550 And Oral Contraception Drug-Drug Interaction Study</brief_title>
	<detailed_description />
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<criteria>Healthy female subject No evidence active latent inadequately treated infection Mycobacterium tuberculosis Any medical reason would contraindicate administration oral contraceptive Clinically significant infection within past 3 month history febrile illness within 5 day Positive screen test Hepatitis B surface antigen , anti Hepatitis C antibody , human immunodeficiency virus Pregnant nursing woman , woman childbearing potential unwilling unable use acceptable method nonhormonal contraception</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>drug interaction</keyword>
	<keyword>CYP3A</keyword>
	<keyword>oral contraceptive</keyword>
	<keyword>anti-rheumatic agent</keyword>
</DOC>